Insights

Innovative Neurotech NeuExcell Therapeutics specializes in cutting-edge gene therapy technology aimed at regenerating neurons in neurodegenerative diseases, presenting opportunities to collaborate with biotech firms or healthcare providers seeking advanced neurological treatments.

Funding Momentum Recent Series Pre-A+ financing of over $15 million indicates strong investor confidence, suggesting the company may be open to strategic partnerships or additional funding opportunities to accelerate product development.

Strategic Partnerships Collaborations like the partnership with Spark Therapeutics highlight NeuExcell’s focus on co-developing treatments for conditions like Huntington’s Disease, opening doors for organizations seeking to co-invest or license innovative gene therapies.

Market Position With a revenue estimate between $10 million and $25 million and rapid R&D expansion, NeuExcell presents a viable customer base for suppliers of biotech research tools, specialized pharmaceuticals, and related technologies targeting neurodegenerative disease treatments.

Growth Potential As a small but rapidly growing biotech firm with a focused mission, NeuExcell offers sales opportunities in areas like research equipment, clinical trial services, and regulatory consulting to support its innovative pipeline and clinical development efforts.

NeuExcell Therapeutics Tech Stack

NeuExcell Therapeutics uses 8 technology products and services including Babel, Google Fonts API, Twemoji, and more. Explore NeuExcell Therapeutics's tech stack below.

  • Babel
    Development
  • Google Fonts API
    Font Scripts
  • Twemoji
    Font Scripts
  • Font Awesome
    Font Scripts
  • jQuery
    Javascript Libraries
  • Yoast SEO
    Search Engines
  • X-XSS-Protection
    Security
  • HTTP/3
    Web & Portal Technology

NeuExcell Therapeutics's Email Address Formats

NeuExcell Therapeutics uses at least 1 format(s):
NeuExcell Therapeutics Email FormatsExamplePercentage
FirstLast@neuexcell.comJohnDoe@neuexcell.com
66%
FirstLa@neuexcell.comJohnDo@neuexcell.com
18%
FLast@neuexcell.comJDoe@neuexcell.com
10%
FirLast@neuexcell.comJohDoe@neuexcell.com
6%

Frequently Asked Questions

What is NeuExcell Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
NeuExcell Therapeutics's official website is neuexcell.com and has social profiles on LinkedIn.

What is NeuExcell Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
NeuExcell Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does NeuExcell Therapeutics have currently?

Minus sign iconPlus sign icon
As of December 2025, NeuExcell Therapeutics has approximately 11 employees across 2 continents, including North AmericaAsia. Key team members include Ceo: J. S.Chief Business And Strategy Officer: L. G.Vice President , Head Of Cmc And Tech Ops: K. Y.. Explore NeuExcell Therapeutics's employee directory with LeadIQ.

What industry does NeuExcell Therapeutics belong to?

Minus sign iconPlus sign icon
NeuExcell Therapeutics operates in the Biotechnology Research industry.

What technology does NeuExcell Therapeutics use?

Minus sign iconPlus sign icon
NeuExcell Therapeutics's tech stack includes BabelGoogle Fonts APITwemojiFont AwesomejQueryYoast SEOX-XSS-ProtectionHTTP/3.

What is NeuExcell Therapeutics's email format?

Minus sign iconPlus sign icon
NeuExcell Therapeutics's email format typically follows the pattern of FirstLast@neuexcell.com. Find more NeuExcell Therapeutics email formats with LeadIQ.

When was NeuExcell Therapeutics founded?

Minus sign iconPlus sign icon
NeuExcell Therapeutics was founded in 2016.

NeuExcell Therapeutics

Biotechnology ResearchPennsylvania, United States11-50 Employees

NeuExcell Therapeutics is a gene therapy company focusing on improving the lives of patients suffering from neurodegenerative diseases. We have discovered a disruptive technology that focuses on regenerating neurons in the brain. This powerful platform has the potential to transform patient outcomes and change lives.

We are now rapidly expanding our R&D efforts, toward our goal of developing effective and safe treatments for serious neurodegenerative diseases including stroke, Huntington’s Disease, ALS, and Traumatic Brain Injury.

Our experienced team is excited to dedicate themselves to contribute and bring innovative and effective treatments for those suffering from neurodegenerative conditions.

It is our goal to improve the quality of life of millions of patients worldwide by using the power of gene therapy to restore damaged neuronal tissue.

Section iconCompany Overview

SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
11-50

Section iconFunding & Financials

  • $10M$25M

    NeuExcell Therapeutics's revenue is estimated to be in the range of $10M$25M

Section iconFunding & Financials

  • $10M$25M

    NeuExcell Therapeutics's revenue is estimated to be in the range of $10M$25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.